Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Joining us today is Panna Sharma, Chief Executive Officer, President and Director of Lantern Pharma, who will guide us through the demonstration and discuss the broader implications of this technology ...
pharmaphorum

Recursion, Exscientia, and AI drug discovery’s moment of truth

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
BioSpace

Patient advocate offers Recursion a powerful reason to keep going in rare disease

Staff at Salt Lake City-based techbio company Recursion recently heard from Jenny and Tim Jones about their challenging ...
pharmaphorum

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
InfoWorld

The front-end architecture trilemma: Reactivity vs. hypermedia vs. local-first apps

Web developers are moving away from the library wars and into a world of architectural choice. It’s about where you want the ...
CNN

Recursion Pharmaceuticals, Inc. Class A

RXRX is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.16 since the market last closed. This is a 4.66 ...